Your session is about to expire
← Back to Search
Atezolizumab for Non-Small Cell Lung Cancer
Study Summary
This trial will investigate if adding atezolizumab to bevacizumab is a safe and effective treatment for patients with stage 4 EGFR mutant NSCLC whose cancer has progressed while taking osimertinib.
- Non-Small Cell Lung Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What other research initiatives have been undertaken to explore Atezolizumab's potential?
"Presently, 621 clinical trials are being conducted on Atezolizumab with 142 in the third phase. Most of these studies take place in Taibei, Taiwan, though there are 31,793 locations around the world where research is taking place."
Are there any known detrimental effects associated with Atezolizumab treatment?
"Atezolizumab was awarded a safety score of 2 on our team's assessment scale, due to the fact that this is only at Phase 2 and there isn't yet any conclusive evidence for efficacy."
Are there any vacancies left for prospective participants in this experiment?
"At this moment in time, no more participants are being recruited for this trial. It was first posted on July 9th 2020 and updated as recently as May 23rd 2022. There is an array of alternatives to consider if you are seeking a clinical study; these include 2114 studies recruiting those with disease progression and 621 trials accepting volunteers who have been prescribed Atezolizumab."
What would Atezolizumab typically be prescribed for?
"Atezolizumab is commonly used to address non-small cell lung carcinoma, recurrent platinum-sensitive ovarian cancer, and postoperative/recurrent occurrences of non-squamous NSCLC."
How many participants are currently being enrolled for this clinical investigation?
"As of now, this trial is not presently recruiting any more individuals. Initially posted on July 9th 2020 and most recently updated on May 23rd 2022, the study has reached its capacity for recruitment. For anyone else interested in participating in a clinical trial, there are 2114 studies actively enrolling patients with disease progression at present and 621 investigations that seek participants taking Atezolizumab as well."
Share this study with friends
Copy Link
Messenger